BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van der Weyden CA, Pileri SA, Feldman AL, Whisstock J, Prince HM. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. Blood Cancer J 2017;7:e603. [PMID: 28885612 DOI: 10.1038/bcj.2017.85] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 17.5] [Reference Citation Analysis]
Number Citing Articles
1 Shea L, Mehta-Shah N. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma. Curr Hematol Malig Rep 2020;15:9-19. [PMID: 32016790 DOI: 10.1007/s11899-020-00561-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
2 Rajendran S, Li Y, Ngoh E, Wong HY, Cheng MS, Wang CI, Schwarz H. Development of a Bispecific Antibody Targeting CD30 and CD137 on Hodgkin and Reed-Sternberg Cells. Front Oncol 2019;9:945. [PMID: 31616638 DOI: 10.3389/fonc.2019.00945] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
3 Fiore D, Cappelli LV, Broccoli A, Zinzani PL, Chan WC, Inghirami G. Peripheral T cell lymphomas: from the bench to the clinic. Nat Rev Cancer 2020;20:323-42. [PMID: 32249838 DOI: 10.1038/s41568-020-0247-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 19.0] [Reference Citation Analysis]
4 Maglie R, Caproni M, Antiga E. Reply to 'Pruritic arthropod bite-like papules in T-cell large granular lymphocytic leukaemia and chronic myelomonocytic leukaemia'. Clin Exp Dermatol 2019;44:75-6. [PMID: 30144144 DOI: 10.1111/ced.13728] [Reference Citation Analysis]
5 Kinch A, Amini RM, Hollander P, Molin D, Sundström C, Enblad G. CD30 expression and survival in posttransplant lymphoproliferative disorders. Acta Oncol 2020;59:673-80. [PMID: 32102582 DOI: 10.1080/0284186X.2020.1731924] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Geri JB, Oakley JV, Reyes-Robles T, Wang T, McCarver SJ, White CH, Rodriguez-Rivera FP, Parker DL Jr, Hett EC, Fadeyi OO, Oslund RC, MacMillan DWC. Microenvironment mapping via Dexter energy transfer on immune cells. Science 2020;367:1091-7. [PMID: 32139536 DOI: 10.1126/science.aay4106] [Cited by in Crossref: 46] [Cited by in F6Publishing: 31] [Article Influence: 46.0] [Reference Citation Analysis]
7 Pileri SA, Tabanelli V, Fiori S, Calleri A, Melle F, Motta G, Lorenzini D, Tarella C, Derenzini E. Peripheral T-Cell Lymphoma, Not Otherwise Specified: Clinical Manifestations, Diagnosis, and Future Treatment. Cancers (Basel) 2021;13:4535. [PMID: 34572763 DOI: 10.3390/cancers13184535] [Reference Citation Analysis]
8 Oliveira JFA, da Silva RF, Ribeiro IRS, Saito Â, Melo‐hanchuk TD, Dias MM, Kobarg J, Cardoso MB. Selective Targeting of Lymphoma Cells by Monoclonal Antibody Grafted onto Zwitterionic‐Functionalized Nanoparticles. Part Part Syst Charact 2020;37:1900446. [DOI: 10.1002/ppsc.201900446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Carminato A, Tecilla M, Roccabianca P, Zanardello C, Melchiotti E, Capello K, Vascellari M. CD30 Cross-Reactivity and Expression in Feline Normal Tissues and Lymphomas. Vet Pathol 2020;57:49-55. [PMID: 31640480 DOI: 10.1177/0300985819875745] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Kasikis S, Etra A, Levine JE. Current and Emerging Targeted Therapies for Acute Graft-Versus-Host Disease. BioDrugs 2021;35:19-33. [PMID: 33201499 DOI: 10.1007/s40259-020-00454-7] [Reference Citation Analysis]
11 Karube K, Kakimoto Y, Tonozuka Y, Ohshima K. The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas. Expert Rev Hematol 2021;:1-11. [PMID: 34263699 DOI: 10.1080/17474086.2021.1955344] [Reference Citation Analysis]
12 Trager MH, Chen C, Husain S, Geskin LJ. Nitrogen mustard gel-induced inflammation triggers lymphomatoid papulosis in patients with mycosis fungoides. J Dermatol 2020;47:546-50. [PMID: 32100361 DOI: 10.1111/1346-8138.15276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Van Der Weyden C, Dickinson M, Whisstock J, Prince HM. Brentuximab vedotin in T-cell lymphoma. Expert Review of Hematology 2018;12:5-19. [DOI: 10.1080/17474086.2019.1558399] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
14 Song Y, Guo Y, Huang H, Li W, Ke X, Feng J, Xu W, Miao H, Kinley J, Song G, Dai Y, Wang H, Zhu J. Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Expert Rev Hematol 2021;:1-9. [PMID: 34275403 DOI: 10.1080/17474086.2021.1942831] [Reference Citation Analysis]
15 Goyal A, Patel S, Goyal K, Morgan EA, Foreman RK. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin. J Cutan Pathol 2019;46:823-9. [PMID: 31286556 DOI: 10.1111/cup.13545] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Suri A, Mould DR, Song G, Kinley J, Venkatakrishnan K. Population Pharmacokinetics of Brentuximab Vedotin in Adult and Pediatric Patients With Relapsed/Refractory Hematologic Malignancies: Model-Informed Hypothesis Generation for Pediatric Dosing Regimens. J Clin Pharmacol 2020;60:1585-97. [PMID: 32596842 DOI: 10.1002/jcph.1682] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Pina-Oviedo S, Ortiz-Hidalgo C, Carballo-Zarate AA, Zarate-Osorno A. ALK-Negative Anaplastic Large Cell Lymphoma: Current Concepts and Molecular Pathogenesis of a Heterogeneous Group of Large T-Cell Lymphomas. Cancers (Basel) 2021;13:4667. [PMID: 34572893 DOI: 10.3390/cancers13184667] [Reference Citation Analysis]
18 Kampa F, Mitteldorf C. A review of CD30 expression in cutaneous neoplasms. J Cutan Pathol 2021;48:495-510. [PMID: 33047376 DOI: 10.1111/cup.13894] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Lyons JJ, Metcalfe DD. Targeting Mast Cells with Biologics. Immunology and Allergy Clinics of North America 2020;40:667-85. [DOI: 10.1016/j.iac.2020.06.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
20 Mei C, Wang X, Meng F, Zhang X, Gan L, Wang Y, Sun X. CD30L+ classical monocytes play a pro-inflammatory role in the development of ulcerative colitis in patients. Mol Immunol 2021;138:10-9. [PMID: 34329889 DOI: 10.1016/j.molimm.2021.06.016] [Reference Citation Analysis]
21 Kahle XU, Montes de Jesus FM, Glaudemans AWJM, Lub-de Hooge MN, Jorritsma-Smit A, Plattel WJ, van Meerten T, Diepstra A, van den Berg A, Kwee TC, Noordzij W, de Vries EGE, Nijland M. Molecular imaging in lymphoma beyond 18F-FDG-PET: understanding the biology and its implications for diagnostics and therapy. Lancet Haematol 2020;7:e479-89. [PMID: 32470439 DOI: 10.1016/S2352-3026(20)30065-X] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Mishra VS, Kumar N, Raza M, Sehrawat S. Amalgamation of PI3K and EZH2 blockade synergistically regulates invasion and angiogenesis: combination therapy for glioblastoma multiforme. Oncotarget 2020;11:4754-69. [PMID: 33473259 DOI: 10.18632/oncotarget.27842] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Witte HM, Merz H, Biersack H, Bernard V, Riecke A, Gebauer J, Lehnert H, von Bubnoff N, Feller AC, Gebauer N. Impact of treatment variability and clinicopathological characteristics on survival in patients with Epstein-Barr-Virus positive diffuse large B cell lymphoma. Br J Haematol 2020;189:257-68. [PMID: 31958882 DOI: 10.1111/bjh.16342] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
24 Gunning WT 3rd, Stepkowski SM, Kramer PM, Karabin BL, Grubb BP. Inflammatory Biomarkers in Postural Orthostatic Tachycardia Syndrome with Elevated G-Protein-Coupled Receptor Autoantibodies. J Clin Med 2021;10:623. [PMID: 33562074 DOI: 10.3390/jcm10040623] [Reference Citation Analysis]
25 Alvarez-Fernández C, Escribà-Garcia L, Caballero AC, Escudero-López E, Ujaldón-Miró C, Montserrat-Torres R, Pujol-Fernández P, Sierra J, Briones J. Memory stem T cells modified with a redesigned CD30-chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma. Clin Transl Immunology 2021;10:e1268. [PMID: 33968404 DOI: 10.1002/cti2.1268] [Reference Citation Analysis]
26 Congras A, Hoareau-Aveilla C, Caillet N, Tosolini M, Villarese P, Cieslak A, Rodriguez L, Asnafi V, Macintyre E, Egger G, Brousset P, Lamant L, Meggetto F. ALK-transformed mature T lymphocytes restore early thymus progenitor features. J Clin Invest 2020;130:6395-408. [PMID: 33141118 DOI: 10.1172/JCI134990] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
27 Matolay O, Beke L, Gyurkovics A, Francz M, Varjasi G, Rejtő L, Illés Á, Bedekovics J, Méhes G. Quantitative Analysis of Carbonic Anhydrase IX Uncovers Hypoxia-Related Functional Differences in Classical Hodgkin Lymphoma Subtypes. Int J Mol Sci 2019;20:E3463. [PMID: 31311071 DOI: 10.3390/ijms20143463] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Turner SD, Inghirami G, Miranda RN, Kadin ME. Cell of Origin and Immunologic Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma. Am J Pathol 2020;190:2-10. [PMID: 31610171 DOI: 10.1016/j.ajpath.2019.09.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
29 Obacz J, Yung H, Shamseddin M, Linnane E, Liu X, Azad AA, Rassl DM, Fairen-Jimenez D, Rintoul RC, Nikolić MZ, Marciniak SJ. Biological basis for novel mesothelioma therapies. Br J Cancer 2021. [PMID: 34226685 DOI: 10.1038/s41416-021-01462-2] [Reference Citation Analysis]
30 Carmon KS, Azhdarinia A. Application of Immuno-PET in Antibody-Drug Conjugate Development. Mol Imaging 2018;17:1536012118801223. [PMID: 30370812 DOI: 10.1177/1536012118801223] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
31 Ahamadi-Fesharaki R, Fateh A, Vaziri F, Solgi G, Siadat SD, Mahboudi F, Rahimi-Jamnani F. Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow. Mol Ther Oncolytics 2019;14:38-56. [PMID: 31011631 DOI: 10.1016/j.omto.2019.02.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
32 Yang S, Wen J, Li H, Xu L, Liu Y, Zhao N, Zeng Z, Qi J, Jiang W, Han W, Zu Y. Aptamer-Engineered Natural Killer Cells for Cell-Specific Adaptive Immunotherapy. Small 2019;15:e1900903. [PMID: 31026116 DOI: 10.1002/smll.201900903] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
33 Suri A, Mould DR, Song G, Collins GP, Endres CJ, Gomez-Navarro J, Venkatakrishnan K. Population Pharmacokinetic Modeling and Exposure-Response Assessment for the Antibody-Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON-1 Study. Clin Pharmacol Ther 2019;106:1268-79. [PMID: 31152605 DOI: 10.1002/cpt.1530] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
34 Argyris PP, Ho D, Islam MN, Khurram SA, Courville EL, Morgan S, Sundick B, Soliman M, Janakiram M, Gopalakrishnan R, Koutlas IG. Self-regressing oral CD30-positive, EBV-negative, T-cell lymphoproliferative lesions. A poorly understood process highlighted by ominous clinicopathologic features and indolent behavior. Oral Surg Oral Med Oral Pathol Oral Radiol 2021;:4638. [PMID: 34526251 DOI: 10.1016/j.oooo.2021.05.014] [Reference Citation Analysis]
35 Huang YH, Chu PY, Chen JL, Huang CT, Huang CC, Tsai YF, Wang YL, Lien PJ, Tseng LM, Liu CY. Expression pattern and prognostic impact of glycoprotein non-metastatic B (GPNMB) in triple-negative breast cancer. Sci Rep 2021;11:12171. [PMID: 34108545 DOI: 10.1038/s41598-021-91588-3] [Reference Citation Analysis]
36 Marchi E, O'Connor OA. The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management. CA Cancer J Clin 2020;70:47-70. [PMID: 31815293 DOI: 10.3322/caac.21589] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
37 Russano de Paiva Silva G, Tournier E, Sarian LO, Bulai-Livideanu C, Delsol G, Lamant L, Vassallo J, Brousset P, Laurent C. Prevalence of CD30 immunostaining in neoplastic mast cells: A retrospective immunohistochemical study. Medicine (Baltimore) 2018;97:e10642. [PMID: 29794740 DOI: 10.1097/MD.0000000000010642] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
38 Hammood M, Craig AW, Leyton JV. Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)-A Necessity for Future ADC Research and Development. Pharmaceuticals (Basel) 2021;14:674. [PMID: 34358100 DOI: 10.3390/ph14070674] [Reference Citation Analysis]
39 Kabasawa N, Shiozawa E, Murai S, Homma M, Uesugi Y, Matsui T, Nakata A, Shimada S, Sasaki Y, Baba Y, Watanuki M, Arai N, Fujiwara S, Kawaguchi Y, Tsukamoto H, Uto Y, Yanagisawa K, Hattori N, Sakai H, Harada H, Nakamaki T, Takimoto M, Yamochi-Onizuka T. Increased MYC expression without MYC gene translocation in patients with the diffuse large B-cell-lymphoma subtype of iatrogenic immunodeficiency-associated lymphoproliferative disorders. J Clin Exp Hematop 2021;61:120-5. [PMID: 34511544 DOI: 10.3960/jslrt.20025] [Reference Citation Analysis]
40 Wei J, Guo Y, Wang Y, Wu Z, Bo J, Zhang B, Zhu J, Han W. Clinical development of CAR T cell therapy in China: 2020 update. Cell Mol Immunol 2021;18:792-804. [PMID: 32999455 DOI: 10.1038/s41423-020-00555-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
41 Schmidt FM, Koch J, Nowak C, Holdt LM, Teupser D, Hegerl U, Himmerich H. Ligands and receptors of the TNF superfamily are decreased in major depression and during early antidepressant therapy. Journal of Psychiatric Research 2019;119:116-21. [DOI: 10.1016/j.jpsychires.2019.09.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
42 Wu Z, Nicoll M, Ingham RJ. AP-1 family transcription factors: a diverse family of proteins that regulate varied cellular activities in classical hodgkin lymphoma and ALK+ ALCL. Exp Hematol Oncol 2021;10:4. [PMID: 33413671 DOI: 10.1186/s40164-020-00197-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Zeng Q, Schwarz H. The role of trogocytosis in immune surveillance of Hodgkin lymphoma. Oncoimmunology 2020;9:1781334. [PMID: 32934884 DOI: 10.1080/2162402X.2020.1781334] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
44 Vega F, Medeiros LJ. A suggested immunohistochemical algorithm for the classification of T-cell lymphomas involving lymph nodes. Hum Pathol 2020;102:104-16. [PMID: 32479842 DOI: 10.1016/j.humpath.2020.05.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
45 André R, Ram-Wolff C, Battistella M, Peffault de Latour R, Petit A, Bouaziz JD, Brice P, Bagot M, de Masson A. Effectiveness of brentuximab vedotin before and after allogeneic stem-cell transplantation in the management of transformed mycosis fungoides. Br J Dermatol 2020;182:1503-4. [PMID: 31854457 DOI: 10.1111/bjd.18806] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
46 Lam JH, Hong M, Koo SL, Chua CWL, Lim KL, Wee F, Wan WK, Leow WQ, Yeo JG, Tan IBH, Yeong J, Lim TKH, Lim TS. CD30+OX40+ Treg is associated with improved overall survival in colorectal cancer. Cancer Immunol Immunother 2021;70:2353-65. [PMID: 33527196 DOI: 10.1007/s00262-021-02859-x] [Reference Citation Analysis]
47 Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol 2021;18:327-44. [PMID: 33558752 DOI: 10.1038/s41571-021-00470-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 28.0] [Reference Citation Analysis]
48 Liebers J, Wurzel P, Reisinger KB, Hansmann ML. 3D image analysis reveals differences of CD30 positive cells and network formation in reactive and malignant human lymphoid tissue (classical Hodgkin Lymphoma). PLoS One 2019;14:e0224156. [PMID: 31648255 DOI: 10.1371/journal.pone.0224156] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Satou A, Bennani NN, Feldman AL. Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. Expert Rev Hematol 2019;12:833-43. [PMID: 31365276 DOI: 10.1080/17474086.2019.1647777] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
50 Leandro MJ. Infections Related to Biologics: Agents Targeting B Cells. Infect Dis Clin North Am 2020;34:161-78. [PMID: 32334986 DOI: 10.1016/j.idc.2020.02.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
51 Xu ML, Gabali A, Hsi ED, Fedoriw Y, Vij K, Salama ME, Ramchandren R, O'Malley D, Wick MR, Battistella M, Gru AA. Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis. Am J Surg Pathol 2020;44:e1-e14. [PMID: 31567279 DOI: 10.1097/PAS.0000000000001368] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
52 Caduff N, McHugh D, Murer A, Rämer P, Raykova A, Landtwing V, Rieble L, Keller CW, Prummer M, Hoffmann L, Lam JKP, Chiang AKS, Raulf F, Azzi T, Berger C, Rubic-Schneider T, Traggiai E, Lünemann JD, Kammüller M, Münz C. Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice. PLoS Pathog 2020;16:e1008477. [PMID: 32251475 DOI: 10.1371/journal.ppat.1008477] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
53 Makawita S, Meric-Bernstam F. Antibody-Drug Conjugates: Patient and Treatment Selection. Am Soc Clin Oncol Educ Book 2020;40:1-10. [PMID: 32213087 DOI: 10.1200/EDBK_280775] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
54 Abe Y, Sugihara K, Nakada T, Shahidi J, Gallant GJA, Jikoh T, Agatsuma T. ADCs on the Market and in Clinical Development. In: Matsumura Y, Tarin D, editors. Cancer Drug Delivery Systems Based on the Tumor Microenvironment. Tokyo: Springer Japan; 2019. pp. 155-74. [DOI: 10.1007/978-4-431-56880-3_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Kovarik JJ, Kämpf AK, Gasser F, Herdina AN, Breuer M, Kaltenecker CC, Wahrmann M, Haindl S, Mayer F, Traby L, Touzeau-Roemer V, Grabmeier-Pfistershammer K, Kussmann M, Robak O, Willschke H, Ay C, Säemann MD, Schmetterer KG, Strassl R. Identification of Immune Activation Markers in the Early Onset of COVID-19 Infection. Front Cell Infect Microbiol 2021;11:651484. [PMID: 34540715 DOI: 10.3389/fcimb.2021.651484] [Reference Citation Analysis]
56 Ramadass V, Vaiyapuri T, Tergaonkar V. Small Molecule NF-κB Pathway Inhibitors in Clinic. Int J Mol Sci 2020;21:E5164. [PMID: 32708302 DOI: 10.3390/ijms21145164] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 22.0] [Reference Citation Analysis]
57 Choi S, Pegues MA, Lam N, Geldres C, Vanasse D, Kochenderfer JN. Design and Assessment of Novel Anti-CD30 Chimeric Antigen Receptors with Human Antigen-Recognition Domains. Hum Gene Ther 2021;32:730-43. [PMID: 33287637 DOI: 10.1089/hum.2020.215] [Reference Citation Analysis]
58 Kreutmair S, Klingeberg C, Poggio T, Andrieux G, Keller A, Miething C, Follo M, Pfeifer D, Shoumariyeh K, Lengerke C, Gonzalez-Menendez I, Fend F, Zeiser R, Turner SD, Quintanilla-Martinez L, Boerries M, Duyster J, Illert AL. Existence of reprogrammed lymphoma stem cells in a murine ALCL-like model. Leukemia 2020;34:3242-55. [PMID: 32203142 DOI: 10.1038/s41375-020-0789-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
59 Packi K, Matysiak J, Matuszewska E, Bręborowicz A, Kycler Z, Matysiak J. New Biomarkers of Hymenoptera Venom Allergy in a Group of Inflammation Factors. Int J Environ Res Public Health 2021;18:4011. [PMID: 33920429 DOI: 10.3390/ijerph18084011] [Reference Citation Analysis]
60 Fitzpatrick MJ, Massoth LR, Marcus C, Vergilio JA, Severson E, Duncan D, Ramkissoon SH, Hasserjian RP, Kim AS, Sohani AR, Williams EA, Nardi V. JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology. Am J Surg Pathol 2021;45:895-904. [PMID: 34105517 DOI: 10.1097/PAS.0000000000001708] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
61 Merlio JP, Kadin ME. Cytokines, Genetic Lesions and Signaling Pathways in Anaplastic Large Cell Lymphomas. Cancers (Basel) 2021;13:4256. [PMID: 34503066 DOI: 10.3390/cancers13174256] [Reference Citation Analysis]
62 Hu B, Oki Y. Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma. Front Oncol 2018;8:139. [PMID: 29761078 DOI: 10.3389/fonc.2018.00139] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
63 Harrop S, Abeyakoon C, Van Der Weyden C, Prince HM. Targeted Approaches to T-Cell Lymphoma. J Pers Med 2021;11:481. [PMID: 34072040 DOI: 10.3390/jpm11060481] [Reference Citation Analysis]
64 Luchtel RA, Zimmermann MT, Hu G, Dasari S, Jiang M, Oishi N, Jacobs HK, Zeng Y, Hundal T, Rech KL, Ketterling RP, Lee JH, Eckloff BW, Yan H, Gaonkar KS, Tian S, Ye Z, Kadin ME, Sidhu J, Jiang L, Voss J, Link BK, Syrbu SI, Facchetti F, Bennani NN, Slager SL, Ordog T, Kocher JP, Cerhan JR, Ansell SM, Feldman AL. Recurrent MSC E116K mutations in ALK-negative anaplastic large cell lymphoma. Blood 2019;133:2776-89. [PMID: 31101622 DOI: 10.1182/blood.2019000626] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
65 Marín I. Tumor Necrosis Factor Superfamily: Ancestral Functions and Remodeling in Early Vertebrate Evolution. Genome Biol Evol 2020;12:2074-92. [PMID: 33210144 DOI: 10.1093/gbe/evaa140] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
66 Butler E, Ludwig K, Pacenta HL, Klesse LJ, Watt TC, Laetsch TW. Recent progress in the treatment of cancer in children. CA Cancer J Clin 2021;71:315-32. [PMID: 33793968 DOI: 10.3322/caac.21665] [Cited by in F6Publishing: 1] [Reference Citation Analysis]